UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011065
Receipt number R000012946
Scientific Title Prophylaxis of febrile neutropenia by reducing chemotherapy-induced gastrointestinal mucosal injury
Date of disclosure of the study information 2013/07/01
Last modified on 2017/07/08 12:40:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prophylaxis of febrile neutropenia by reducing chemotherapy-induced gastrointestinal mucosal injury

Acronym

Prophylaxis of febrile neutropenia

Scientific Title

Prophylaxis of febrile neutropenia by reducing chemotherapy-induced gastrointestinal mucosal injury

Scientific Title:Acronym

Prophylaxis of febrile neutropenia

Region

Japan


Condition

Condition

febrile neutropenia

Classification by specialty

Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To prevent febrile neutropenia in pediatric patients undergoing chemotherapy for malicnancies with prophylactic use of synbiotics and glutamine.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase III


Assessment

Primary outcomes

incidence of febrile neutropenia

Key secondary outcomes

severity of gastrointestinal mucosal
injury

stability of intestinal environments


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

No treatment

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

4

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

oral administration of synbiotics

Interventions/Control_2

oral administration of glutamine

Interventions/Control_3

oral administration of synbiotics and glutamine

Interventions/Control_4

control

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

6 months-old <=

Age-upper limit

216 months-old >

Gender

Male and Female

Key inclusion criteria

patients admitted for cancer chemotherapy which is expected to cause neutropenia

Key exclusion criteria

patients with underlying infection before developping neutropenia

patients who is allergic to probiotics or glutamine

Target sample size

75


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toshiaki Shimizu

Organization

Juntendo University School of Medicine

Division name

Department of Pediatrics and Adolescent Medicine

Zip code


Address

2-1-1 Hongo, Bunkyo-ku, Tokyo , Japan

TEL

03-3813-3111

Email

tkurashi@juntendo.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Tomoko Kurimoto

Organization

Juntendo University School of Medicine

Division name

Department of Pediatrics and Adolescent Medicine

Zip code


Address

2-1-1 Hongo, Bunkyo-ku, Tokyo , Japan

TEL

03-3813-3111

Homepage URL


Email

tkurashi@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)

Yakult Central Institute for Microbiological Research


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

順天堂大学医学部附属順天堂医院(東京都)


Other administrative information

Date of disclosure of the study information

2013 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2014 Year 01 Month 31 Day

Date of IRB


Anticipated trial start date

2014 Year 02 Month 01 Day

Last follow-up date

2016 Year 09 Month 30 Day

Date of closure to data entry

2017 Year 02 Month 24 Day

Date trial data considered complete

2017 Year 04 Month 30 Day

Date analysis concluded

2018 Year 04 Month 30 Day


Other

Other related information



Management information

Registered date

2013 Year 06 Month 28 Day

Last modified on

2017 Year 07 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012946


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name